Introduction
Transverse myelitis (TM) is a rare inflammatory condition affecting the spinal cord, characterized by a rapid onset of neurological symptoms that necessitate prompt and accurate Tm Diagnosis. As specialists in automotive repair transitioning our expertise to medical content, we understand the critical importance of precise diagnostics – whether for vehicles or the human body. This guide delves into the comprehensive evaluation process for TM, a condition that, like complex automotive issues, requires a systematic approach to identify and manage effectively. TM often manifests with weakness, sensory disturbances, and bowel/bladder dysfunction, emerging either independently, frequently post-infection, or as part of broader neuro-inflammatory syndromes such as acute disseminated encephalomyelitis, multiple sclerosis, neuromyelitis optica spectrum disorder, and acute flaccid myelitis. Predominantly impacting the thoracic spinal cord, TM’s effects can range from temporary impairment lasting 3 to 6 months to permanent disability. Accurate and timely TM diagnosis is paramount to guide appropriate management and improve patient outcomes.
Etiology of Transverse Myelitis
Understanding the causes of TM is crucial for effective TM diagnosis and management. The etiology of TM is diverse, broadly categorized as idiopathic, post-infectious, systemic inflammatory, or related to multifocal central nervous system diseases. Idiopathic TM, where no specific cause is identified, is the most prevalent. Infections known to trigger TM include a range of viruses and bacteria such as enteroviruses, West Nile virus, herpes viruses, HIV, human T-cell leukemia virus type 1 (HTLV-1), Zika virus, neuroborreliosis (Lyme disease), Mycoplasma, and Treponema pallidum. Furthermore, autoimmune disorders of the central nervous system, including multiple sclerosis, neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelitis, are recognized associations. Systemic inflammatory autoimmune conditions like ankylosing spondylitis, antiphospholipid syndrome, Behçet disease, mixed connective tissue disease, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren syndrome, and systemic lupus erythematosus also have reported links to TM. A thorough investigation into these potential etiologies is a vital component of the TM diagnosis process, helping to differentiate TM from other myelopathies and guide subsequent treatment strategies.
Epidemiology of TM
Epidemiological data provides valuable context for TM diagnosis, highlighting population-level patterns that can inform clinical suspicion. TM affects men and women equally, although associations with multiple sclerosis may show a female predominance. The condition can occur across all age groups, with notable incidence peaks around ages 10, 20, and beyond 40, exhibiting a bimodal distribution between 10-19 and 30-39 years. The annual incidence of TM is estimated at 1 to 8 new cases per million individuals. Notably, occurrence rates do not significantly differ between Euro/American-born and Afro/Asian-born populations. Studies indicate that idiopathic TM (primary TM) accounts for a substantial proportion of cases, ranging from 15% to 64% in different reports, while the remainder are classified as secondary TM, linked to an underlying disease. These epidemiological insights are essential for healthcare professionals to consider when evaluating patients for potential TM diagnosis, especially in the context of differential diagnosis and risk assessment.
Histopathology of Transverse Myelitis
Histopathological findings offer deeper insights into the disease mechanisms underlying TM, contributing to a more nuanced understanding of TM diagnosis and pathology. The histopathology of TM is variable, reflecting the diverse underlying causes. Classical descriptions often highlight perivascular infiltration, demyelination, and axonal injury at the lesion site, mediated by monocytes and lymphocytes. However, the heterogeneity observed, with involvement of both gray and white matter, suggests TM is not solely a demyelinating disorder. It appears to be a complex inflammatory process affecting neurons, axons, oligodendrocytes, and myelin. Alternative histopathological mechanisms, such as molecular mimicry and superantigen-mediated disease, have been implicated, particularly in autoimmune-related TM. These microscopic features are not directly used for routine TM diagnosis in clinical practice but are crucial for research and for differentiating TM from other spinal cord pathologies at a cellular level.
History and Physical Examination in TM Diagnosis
A detailed patient history and thorough physical examination are foundational steps in the TM diagnosis process. The onset of TM is typically acute to subacute, marked by prominent neurological symptoms affecting motor, sensory, and autonomic functions. Motor deficits manifest as rapidly progressing paraparesis, potentially involving the upper extremities initially with flaccidity, evolving into spasticity. Sensory involvement is common, presenting as pain, dysesthesia, and paresthesia at the affected spinal level. Autonomic symptoms include urinary urgency, bladder/bowel incontinence, voiding difficulties, constipation, and sexual dysfunction. Urinary retention can be an early indicator, prompting further investigation for myelopathy and guiding toward a potential TM diagnosis.
Motor symptom presentation varies with the spinal cord level affected. Upper cervical lesions (C1-C5) can impact all four limbs and, if involving the phrenic nerve (C3-C5), may lead to respiratory failure. Lower cervical lesions (C5-T1) might show upper and lower motor neuron signs in the upper limbs and upper motor neuron signs in the lower limbs. Cervical lesions account for about 20% of TM cases. Thoracic lesions (T1-T12), the most common (70%), typically cause upper and lower motor neuron signs in the lower extremities. Lumbosacral lesions (L1-S5) can also result in upper and lower motor neuron signs in the legs, representing approximately 10% of cases. Sensory symptoms usually correspond to the lesion level or adjacent levels. Back pain in the lesion area may also be present. These clinical features gathered from history and physical examination are crucial for initial TM diagnosis consideration and directing further diagnostic evaluations.
Evaluation and Diagnostic Criteria for TM
The evaluation process for TM diagnosis is systematic, aimed at confirming the condition and excluding other possibilities. Initially, it’s critical to rule out compressive spinal cord lesions, typically achieved through magnetic resonance imaging (MRI).
Figure: Spine MRI, T2 Axial TM. This T2-weighted axial MRI image of the spine demonstrates the characteristic hyperintense signal within the spinal cord indicative of transverse myelitis. The image aids in visualizing the extent and location of inflammation, crucial for TM diagnosis.
Confirmation of inflammation follows, often via gadolinium-enhanced MRI or lumbar puncture (LP). Diagnostic criteria exist, primarily for research, as not all criteria must be met for clinical TM diagnosis.
Key diagnostic criteria include:
- Sensory, motor, or autonomic dysfunction originating from the spinal cord.
- T2 hyperintense signal changes on MRI.
- Exclusion of compressive lesions.
- Bilateral signs and symptoms.
- Clearly defined sensory level.
- Gadolinium enhancement on MRI and CSF analysis showing inflammation (pleocytosis or elevated IgG index).
- Symptom progression to peak severity between 4 hours and 21 days.
Recommended investigative analyses when considering TM diagnosis are:
- MRI of the entire spine with and without gadolinium contrast: Differentiates compressive from non-compressive lesions and visualizes inflammation extent.
- Brain MRI with and without gadolinium contrast: Evaluates for brain lesions, important in differentiating TM from conditions like multiple sclerosis.
- Lumbar puncture (LP) for CSF analysis: Includes cell count, protein, glucose, VDRL test, oligoclonal bands, IgG index, and cytology to confirm inflammation and rule out infection.
- Serum blood tests: Anti-aquaporin-4 (APQ-4)-IgG and anti-myelin oligodendrocyte glycoprotein autoantibodies, B12 level, methylmalonic acid, ANA, Ro/SSA, La/SSB autoantibodies, syphilis serologies, HIV antibodies, TSH, and viral etiology tests as indicated.
In patients with longitudinally extensive spinal cord lesions, additional studies are needed:
- Serum erythrocyte sedimentation rate, C-reactive protein, ANA, extractable nuclear antigens antibodies, rheumatoid factor, antiphospholipid antibodies, and antineutrophil cytoplasmic antibodies.
- Chest computed tomography to evaluate for sarcoidosis.
Further testing may be guided by specific clinical scenarios, contributing to a definitive TM diagnosis. These may include neuro-ophthalmologic evaluation, paraneoplastic evaluation, infectious serologic and CSF studies, nasopharyngeal swab for enteroviral PCR, serum copper and ceruloplasmin, vitamin B12 and E levels, spinal angiogram, prothrombotic evaluation, and salivary gland biopsy. This comprehensive evaluation ensures accurate TM diagnosis and differentiation from similar conditions.
Treatment and Management of Transverse Myelitis
Prompt treatment is crucial following TM diagnosis to mitigate the effects of the condition. The cornerstone of initial therapy is high-dose intravenous glucocorticoids, administered as early as possible. Delaying treatment for test results is generally discouraged due to the importance of immediate inflammation control. Glucocorticoid therapy, such as methylprednisolone or dexamethasone for 3 to 5 days, has few contraindications. The duration of therapy is adjusted based on clinical progression.
Plasma exchange is considered effective for acute central nervous system demyelinating diseases unresponsive to glucocorticoids and may be utilized in refractory TM cases post TM diagnosis. As understanding of TM evolves, immunomodulatory therapies like cyclophosphamide, mycophenolate, or rituximab are increasingly considered for chronic recurrent or resistant acute TM. Supportive management strategies are integral to TM care and include pain management, intravenous immunoglobulin, and antiviral medications as appropriate based on the suspected etiology identified during TM diagnosis.
Differential Diagnosis of TM
Differential diagnosis is a critical step in confirming TM diagnosis, as several conditions can mimic its presentation. Any disease causing myelopathy should be considered, including compressive myelopathy from herniated discs, vertebral body compression fractures, epidural abscesses/masses, and spondylitis. Vascular, metabolic/nutritional, neoplastic, and radiation-induced myelopathies also fall into the differential. Infectious and autoimmune diseases, when underlying causes of secondary TM, need to be differentiated and treated accordingly. Guillain-Barré syndrome should also be considered in the differential, especially in the initial stages of evaluation for TM diagnosis. A systematic approach to differential diagnosis ensures accurate identification of TM and rules out other treatable conditions.
Prognosis of Transverse Myelitis
Prognosis following TM diagnosis is variable, with most patients experiencing at least partial recovery, particularly in idiopathic TM cases. Recovery typically begins within 1 to 3 months and may continue for up to two years, often enhanced by exercise and rehabilitation therapy. However, some degree of persistent disability may occur in approximately 40% of cases. Rapid onset with complete paraplegia and spinal shock is associated with a less favorable prognosis. While most patients experience TM as a monophasic illness, recurrence is possible, especially in chronic or secondary TM forms. The majority of recovery happens within the first 3 months of symptom onset; limited recovery after 3 to 6 months suggests a lower likelihood of significant further improvement. Understanding the prognostic factors associated with TM diagnosis helps manage patient expectations and guide rehabilitation planning.
Complications of TM
Following TM diagnosis, patients are at risk for several complications that require ongoing management. These include chronic urinary tract infections, decubitus ulcers, chronic pain, spasticity, major depression, and sexual dysfunction. Notably, 5% to 10% of patients initially diagnosed with acute complete TM may later develop multiple sclerosis, although this often reflects multiple sclerosis presenting as TM initially. Long-term monitoring and proactive management of these potential complications are essential components of post-TM diagnosis care.
Deterrence and Patient Education for TM
While TM itself is not preventable, patient education plays a vital role in managing expectations and improving outcomes after TM diagnosis. Educating patients about the prognosis, disease course, diagnostic process, and treatment options is crucial. Counseling on the risks and benefits of high-dose steroids is particularly important. Patients should understand the natural disease course: approximately one-third achieve full recovery, one-third partial recovery, and one-third may experience permanent disabilities. It’s also important to convey that TM is often a single episode illness, with recurrence more likely when secondary to a chronic comorbidity. Current acute TM treatments primarily involve steroids and immunosuppression, with promising monoclonal antibody therapies under investigation. Emphasize the importance of intensive physical and occupational therapy post-TM diagnosis to maximize functional recovery.
Enhancing Healthcare Team Outcomes in TM Management
Optimal outcomes in TM management, starting from accurate TM diagnosis through rehabilitation, are best achieved through an interprofessional healthcare team approach. This holistic, integrated strategy ensures comprehensive care throughout the acute and post-acute phases. Physical and occupational therapy are indispensable for recovery, with early integration and continuity from inpatient to rehabilitation settings significantly improving patient outcomes. For patients achieving meaningful recovery, independence is best facilitated through intensive therapy to regain lost function. Care coordination across hospital and outpatient services ensures smooth transitions. Social worker consultation aids in arranging necessary durable medical equipment before discharge. Pharmacists contribute by counseling on medication side effects and managing drug interactions. This collaborative, team-based approach is essential for optimizing care and improving quality of life for individuals following a TM diagnosis.
Review Questions
Access free multiple choice questions on this topic.
References
1.West TW, Hess C, Cree BA. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012 Apr;32(2):97-113. [PubMed: 22961185]
2.Krishnan C, Kaplin AI, Pardo CA, Kerr DA, Keswani SC. Demyelinating disorders: update on transverse myelitis. Curr Neurol Neurosci Rep. 2006 May;6(3):236-43. [PubMed: 16635433]
3.Beh SC, Greenberg BM, Frohman T, Frohman EM. Transverse myelitis. Neurol Clin. 2013 Feb;31(1):79-138. [PMC free article: PMC7132741] [PubMed: 23186897]
4.Neri VC, Xavier MF, Barros PO, Melo Bento C, Marignier R, Papais Alvarenga R. Case Report: Acute Transverse Myelitis after Zika Virus Infection. Am J Trop Med Hyg. 2018 Dec;99(6):1419-1421. [PMC free article: PMC6283478] [PubMed: 30277201]
5.Oh DH, Jun JB, Kim HT, Lee SW, Jung SS, Lee IH, Kim SY. Transverse myelitis in a patient with long-standing ankylosing spondylitis. Clin Exp Rheumatol. 2001 Mar-Apr;19(2):195-6. [PubMed: 11326484]
6.de Seze J, Lanctin C, Lebrun C, Malikova I, Papeix C, Wiertlewski S, Pelletier J, Gout O, Clerc C, Moreau C, Defer G, Edan G, Dubas F, Vermersch P. Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology. 2005 Dec 27;65(12):1950-3. [PubMed: 16380618]
7.Mok CC, Lau CS. Transverse myelopathy complicating mixed connective tissue disease. Clin Neurol Neurosurg. 1995 Aug;97(3):259-60. [PubMed: 7586861]
8.Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker BG., Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Dec 13;77(24):2128-34. [PubMed: 22156988]
9.ALTROCCHI PH. ACUTE TRANSVERSE MYELOPATHY. Arch Neurol. 1963 Aug;9:111-9. [PubMed: 14048158]
10.Berman M, Feldman S, Alter M, Zilber N, Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology. 1981 Aug;31(8):966-71. [PubMed: 7196523]
11.Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist. 2005 Jan;11(1):2-18. [PubMed: 15631640]
12.West TW. Transverse myelitis–a review of the presentation, diagnosis, and initial management. Discov Med. 2013 Oct;16(88):167-77. [PubMed: 24099672]
13.Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002 Aug 27;59(4):499-505. [PubMed: 12236201]
14.Weinshenker BG, O’Brien PC, Petterson TM, Noseworthy JH, Lucchinetti CF, Dodick DW, Pineda AA, Stevens LN, Rodriguez M. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 Dec;46(6):878-86. [PubMed: 10589540]
15.Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011 Jan 18;76(3):294-300. [PMC free article: PMC3034395] [PubMed: 21242498]
16.Defresne P, Hollenberg H, Husson B, Tabarki B, Landrieu P, Huault G, Tardieu M, Sébire G. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol. 2003 Jun;18(6):401-6. [PubMed: 12886975]
17.Pidcock FS, Krishnan C, Crawford TO, Salorio CF, Trovato M, Kerr DA. Acute transverse myelitis in childhood: center-based analysis of 47 cases. Neurology. 2007 May 01;68(18):1474-80. [PubMed: 17470749]
18.Bruna J, Martínez-Yélamos S, Martínez-Yélamos A, Rubio F, Arbizu T. Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. Mult Scler. 2006 Apr;12(2):169-73. [PubMed: 16629419]
19.Chen L, Li J, Guo Z, Liao S, Jiang L. Prognostic indicators of acute transverse myelitis in 39 children. Pediatr Neurol. 2013 Dec;49(6):397-400. [PubMed: 24112847]
Disclosure: Christopher Simone declares no relevant financial relationships with ineligible companies.
Disclosure: Prabhu Emmady declares no relevant financial relationships with ineligible companies.
